Terms ending in 2033
Every in-force patent on Genentech, Inc.'s record whose computed term ends in 2033, whoever holds it now. Soonest term end first, then patent number.
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 8,716,236 | Inhibitors of Iap In force · High confidence | Genentech, Inc. | In force | High confidence | |
| US 9,238,675 | Inhibitors of Iap In force · High confidence | Genentech, Inc. | In force | High confidence | |
| US 9,586,991 | Inhibitors of Iap In force · High confidence | Genentech, Inc. | In force | High confidence | |
| US 11,096,982 | Inhibitors of Iap In force · High confidence | Genentech, Inc. | In force | High confidence | |
| US 11,963,994 | Inhibitors of Iap In force · Medium confidence | Genentech, Inc. | In force | Medium confidence | |
| US 11,873,330 | Cysteine Engineered Antibodies and Conjugates In force · High confidence | Genentech, Inc. | In force | High confidence | |
| US 10,646,567 | Methods of Treating Cancer Using PD-1 Axis Binding Antagonists and Mek Inhibitors In force · Medium confidence | Genentech, Inc. | In force | Medium confidence | |
| US 9,200,072 | ANTI-LRP5 Antibodies and Methods of Use In force · High confidence | F. Hoffmann-La Roche AG | In force | High confidence | |
| US 10,035,854 | Method of Treating Retinopathy with an ANTI-LRP5 Antibody In force · High confidence | Genentech, Inc. | In force | High confidence | |
| US 9,862,778 | Assembly of Bispecific Antibodies In force · High confidence | Genentech, Inc. | In force | High confidence | |
| 66 more term ends in 2033 · Pro | |||||
10 of 76 patents shown. Soonest term end first, then patent number.
Pro members see all 76.
61 of these are in force and held by Genentech, Inc..
Updated Nov 17, 2026 · includes USPTO assignment data published Nov 16, 2026, status data published Nov 17, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.